[Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod]

Juan Guillermo Ariza; Jairo Andrés Martínez

[Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod]

Rev Gastroenterol Peru. 2006 Jan-Mar;26(1):77-9.

[Article in Spanish]

Authors

Juan Guillermo Ariza¹, Jairo Andrés Martínez

Affiliation

¹ Universidad de la Sabana.

PMID: 16622489

Abstract

Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently Tagaserod an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.

Publication types

English Abstract
Review

MeSH terms

Humans
Indoles / economics*
Indoles / therapeutic use*
Irritable Bowel Syndrome / drug therapy*
Irritable Bowel Syndrome / economics*
Serotonin Receptor Agonists / economics*
Serotonin Receptor Agonists / therapeutic use*
Treatment Outcome

Substances

Indoles
Serotonin Receptor Agonists
tegaserod